Baishideng Publishing Group Co., Limited
Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report
Name of Journal: World Journal of Gastroenterology
ESPS Manuscript NO: 6294
Title: Current and future molecular diagnostics in colorectal cancer and colorectal adenoma
Reviewer code: 00227433
Science editor: Ma, Ya-Juan
Date sent for review: 2013-10-14 22:13
Date reviewed: 2013-11-15 18:23

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
[Y] Grade A (Excellent)	[ ] Grade A: Priority Publishing	Google Search:	[Y] Accept
[ ] Grade B (Very good)	[Y] Grade B: minor language polishing	[ ] Existed	[ ] High priority for publication
[ ] Grade C (Good)	[ ] Grade C: a great deal of language polishing	[ ] No records	[ ]Rejection
[ ] Grade D (Fair)	[ ] Grade D: rejected	BPG Search:	[ ] Minor revision
[ ] Grade E (Poor)		[ ] Existed	[ ] Major revision
		[ ] No records	

COMMENTS TO AUTHORS
This is an excellent and comprehensive review of evidence on molecular diagnostics in colorectal cancer. My only suggestions for improvement would be to include more detail on the sensitivity/specificity of each of the molecular diagnostic tests discussed, and to consider inclusion of a table to summarise the markers discussed, with a comment on the quality of evidence currently available.

Baishideng Publishing Group Co., Limited
Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report
Name of Journal: World Journal of Gastroenterology
ESPS Manuscript NO: 6294
Title: Current and future molecular diagnostics in colorectal cancer and colorectal adenoma
Reviewer code: 00054975
Science editor: Ma, Ya-Juan
Date sent for review: 2013-10-14 22:13
Date reviewed: 2013-11-29 16:46

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
[ ] Grade A (Excellent)	[ ] Grade A: Priority Publishing	Google Search:	[ ] Accept
[ ] Grade B (Very good)	[Y] Grade B: minor language polishing	[ ] Existed	[ ] High priority for publication
[Y] Grade C (Good)	[ ] Grade C: a great deal of language polishing	[ ] No records	
[ ] Grade D (Fair)		BPG Search:	[ ]Rejection
[ ] Grade E (Poor)	[ ] Grade D: rejected	[ ] Existed	[Y] Minor revision
		[ ] No records	[ ] Major revision

COMMENTS TO AUTHORS

This is a nice overview. I believe it can be improved by addressing the following: - It is not sure whether the same markers can be used to detect adenomas and cancers, and even if it can detect neoplasia in different sites in the colon, please discuss. - TP53 is mentioned as a marker but with no relation to CRC, amnd I doubt anyone would suggest this to be a good and specific marker for coloncancer. Please discuss or remove as you see fit. - Please discuss the current evidence for detecting adenomas/cancers by various fecla tests, be it occult blood or occult genes. What are the evidence, the costs and the current sensitivity/specificity for such testing? - The section on methods used for molecular eating is good. What about immunohistochemistry for MSI testing/screening? Any role compared to the mentioned PCR methods? Please discuss. - I would suggest to address the features and role of hereditary syndromes (HNPCC, FAP) in a separate paragraph, and then discuss CRC on the basis of sporadic cases if that is your intention. Some aspects of hereditary clinical and molecular features may not apply to the sporadic, symptomatic screening setting, so this needs to be highlighted. - Maybe include a few words on the "rules and roles" of developing novel biomarkers - what about testing, validating etc the biomarker panels, any suggested guidelines that should be followed etc? - Figures 1 and 2 is overly simplified and should dbetter be combined to demonstrate the true complexity of CRC development and different classifications. Minors: p. 7: a typo for MSI (is written MIS) p. 7 and ff: greek letters (beta, alpha etc) are marked as squares in the document, may be due to the typesetting, please correct.

Baishideng Publishing Group Co., Limited
Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report
Name of Journal: World Journal of Gastroenterology
ESPS Manuscript NO: 6294
Title: Current and future molecular diagnostics in colorectal cancer and colorectal adenoma
Reviewer code: 00057100
Science editor: Ma, Ya-Juan
Date sent for review: 2013-10-14 22:13
Date reviewed: 2013-11-30 09:49

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
[Y] Grade A (Excellent)	[Y] Grade A: Priority Publishing	Google Search:	[Y] Accept
[ ] Grade B (Very good)	[ ] Grade B: minor language polishing	[ ] Existed	[ ] High priority for publication
[ ] Grade C (Good)	[ ] Grade C: a great deal of language polishing	[ ] No records	
[ ] Grade D (Fair)		BPG Search:	[ ]Rejection
[ ] Grade E (Poor)	[ ] Grade D: rejected	[ ] Existed	[ ] Minor revision
		[ ] No records	[ ] Major revision

COMMENTS TO AUTHORS
Dear Editor: I have read with interest the manuscript entitled Current and future molecular diagnostics in colorectal cancer and colorectal adenoma by Andy Hin-Fung Tsang and coworkers. It is a very interesting topic for clinicians, oncologist, surgeons and gastroenterologist. It is very well written and should be published in WJG.

Baishideng Publishing Group Co., Limited
Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report
Name of Journal: World Journal of Gastroenterology
ESPS Manuscript NO: 6294
Title: Current and future molecular diagnostics in colorectal cancer and colorectal adenoma
Reviewer code: 00057665
Science editor: Ma, Ya-Juan
Date sent for review: 2013-10-14 22:13
Date reviewed: 2013-11-30 23:00

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
[ ] Grade A (Excellent)	[Y] Grade A: Priority Publishing	Google Search:	[Y] Accept
[Y] Grade B (Very good)	[ ] Grade B: minor language polishing	[ ] Existed	[ ] High priority for publication
[ ] Grade C (Good)	[ ] Grade C: a great deal of language polishing	[ ] No records	
[ ] Grade D (Fair)		BPG Search:	[ ]Rejection
[ ] Grade E (Poor)	[ ] Grade D: rejected	[ ] Existed	[ ] Minor revision
		[ ] No records	[ ] Major revision

COMMENTS TO AUTHORS
This is a timely review on colorectal cancer biomarkers. I congratulate the authors

Baishideng Publishing Group Co., Limited
Flat C, 23/F., Lucky Plaza,
315-321 Lockhart Road,
Wan Chai, Hong Kong, China

ESPS Peer-review Report
Name of Journal: World Journal of Gastroenterology
ESPS Manuscript NO: 6294
Title: Current and future molecular diagnostics in colorectal cancer and colorectal adenoma
Reviewer code: 00068897
Science editor: Ma, Ya-Juan
Date sent for review: 2013-10-14 22:13
Date reviewed: 2013-12-02 16:10

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
[ ] Grade A (Excellent)	[Y] Grade A: Priority Publishing	Google Search:	[ ] Accept
[ ] Grade B (Very good)	[ ] Grade B: minor language polishing	[ ] Existed	[ ] High priority for publication
[Y] Grade C (Good)	[ ] Grade C: a great deal of language polishing	[ ] No records	[ ]Rejection
[ ] Grade D (Fair)	[ ] Grade D: rejected	BPG Search:	[Y] Minor revision
[ ] Grade E (Poor)		[ ] Existed	[ ] Major revision
		[ ] No records	

COMMENTS TO AUTHORS
Major Compulsory Revisions 1. This paper reviews molecular diagnostics in colorectal cancer but the results are presented in a very flat manner. i) The authors seem to focus on methodological principles rather than clinical implication. They should explain the clinical benefits for the field of action. This must be revised. ii) While the authors discuss about clinical biomarkers such as CEA in the "Summary" section, they didn't show any comments on it in the text. The summary is completely different to the contents of body text. They should properly address the status quo of clinical biomarkers in the text. 2. As the review for diagnostic and prognostic markers are mixed in the text, readers will be confused. The authors should rewrite the text to make it clear. Minor Revisions 1. Molecular Basis of Colorectal Cancer: 2nd sentence: Adenoma-carcinoma sequence was advocated by Dr Vogelstein's team in Cell, 1990. Please correct the reference. 2. RAS family: Recent clinical trials have started to focus HRAS and BRAF as well as KRAS. Please address the state-of –the-art topics about these genes. 3. Figure Legends: At least, Figures 2 and 5 are not original, as far as I can confirm. The authors should note the original references in the legends. 4. Itemization is treated roughly. For example, "Methods of miRNA Detection", "Quantitative Reverse Transcription PCR", "Microarray", and "Lateral Flow Nucleic Acid Assay" should belong to "MicroRNA Markers" section in pp.14. Itemization should be carefully performed.